Literature DB >> 10726975

Programmed cell death in post-traumatic bone callus.

M L Olmedo1, P S Landry, K K Sadasivan, J A Albright, A A Marino.   

Abstract

Some osteoblasts in the expanded population of periosteal cells that occurs following bone injury are removed from the callus by apoptosis. Our objective was to study whether the consequences of activation of the death program could include feedback control of the healing response. Transforming growth factor beta and interleukin-1beta were delivered together continuously to a standardized tibial defect in rats for 3 days using implanted micro-osmotic pumps. The bones were recovered at 1, 2, 3, 5, 7, 10 and 14 days after injury (n = 6 in each treated and control group) and concentrations of proliferating cells, osteoblasts and apoptotic bodies were determined. The injury-induced apoptotic component of the healing response was shifted in time due to the combined cytokines, compared with vehicle only, with the result that the peak in the concentration of apoptotic bodies occurred 2-3 days earlier in the treated animals. Neither osteoprogenitor proliferation nor osteoblast concentration was affected by addition of the cytokines. The results suggested that activation of apoptosis during injury repair was not necessarily a passive consequence of the cellular response to injury. Programmed cell death could therefore have an active role in modulating bone repair.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10726975

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  2 in total

1.  Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism.

Authors:  John Street; Brian Lenehan
Journal:  J Orthop Surg Res       Date:  2009-06-16       Impact factor: 2.359

2.  Duffy antigen receptor for chemokines regulates post-fracture inflammation.

Authors:  Charles H Rundle; Subburaman Mohan; Bouchra Edderkaoui
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.